Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: A meta-analysis

Diabetes Care

Volumn 40, Issue 11, 2017, Pages 1588-1596

  Khunti, Kamlesh ^a   Seidu, Samuel ^a   Kunutsor, Setor ^b   Davies, Melanie ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CLINICAL RESEARCH; DISEASE ASSOCIATION; HOSPITALIZATION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; CHRONIC DISEASE; MEDICATION COMPLIANCE; MORTALITY; RISK FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 85033225059     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1925     Document Type: Article

References (55)

1. Osterberg L, Blaschke T. Adherence tomedication. N Engl J Med 2005;353:487-497
2. DiMatteo MR. Variations in patients' adherence to medical recommendations: A quantitative reviewof 50 years of research. Med Care 2004;42: 200-209
3. Cramer J, Rosenheck R, KirkG, KrolW, Krystal J; VANaltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6: 566-573
4. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999;17:1041-1045
5. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310
6. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-1224
7. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000;160:3278-3285
8. MarcumZA, GelladWF. Medication adherence to multidrug regimens. Clin GeriatrMed 2012;28: 287-300
9. Gallacher KI, Batty GD, McLean G, et al. Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1, 424, 378 patients in Scotland: implications for treatment burden. BMC Med 2014;12:151
10. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95:68-71
11. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: A retrospective cohort study. Diabet Med 2002;19:279-284
12. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
14. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358: 2560-2572
15. BoussageonR, Bejan-Angoulvant T, Saadatian-ElahiM, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169
16. Care Quality Commission. The State of Health Care and Adult Social Care in England in 2011/12. London, The Stationery Office, 2012
17. Stone MA, Charpentier G, Doggen K, et al.; GUIDANCE Study Group. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care 2013;36:2628-2638
18. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U. S. diabetes care, 1999-2010. N Engl JMed 2013; 368:1613-1624
19. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15
20. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings fromthe Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl. 1):25-32
21. RheeMK, SlocumW, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-250
22. Wagner JH, Justice AC, ChesneyM, Sinclair G, Weissman S, Rodriguez-Barradas M; VACS 3 Project Team. Patient-and provider-reported adherence: Toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol 2001;54(Suppl. 1):S91-S98
23. Alcoba M, Cuevas MJ, Perez-Simon M-R, et al.; HAART Adherence Working Group for the Province of Leon, Spain. Assessment of adherence to triple antiretroviral treatment including indinavir: role of the determination of plasma levels of indinavir. J Acquir Immune Defic Syndr 2003;33:253-258
24. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-3035
25. Stroup DF, Berlin JA, Morton SC, et al. Metaanalysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012
26. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009;151:264-269, W64
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias inmeta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634
30. Sterne J, Becker B, EggerM. The funnel plot. In Publication Bias in Meta-analysis: Prevention, Assessment and Adjustments. Rothstein H, Sutton A, Borenstein M, Eds. Chichester, U. K., Wiley, 2005
31. Wells GASB, O'Connell D, Peterson JE, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies inmeta-analyses, 2000. Available from http://www. ohri. ca/programs/ clinical-epidemiology/oxford. Asp. Accessed 20 May 2017
32. Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16: 589-600
33. Hong JS, Kang HC. Relationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South Korea. Med Care 2011;49:378-384
34. Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs The case of diabetes. Adv Health Econ Health Serv Res 2010;22:151-173
35. Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood) 2012; 31:1836-1846
36. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27:2149-2153
37. White TJ, Vanderplas A, Chang E, Dezii CM, Abrams GD. The costs of non-adherence to oral antihyperglycemic medication in individuals with diabetes mellitus and concomitant diabetes mellitus and cardiovascular disease in amanaged care environment. Disease Management & Health Outcomes 2004;12:181-188
38. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-1841
39. Zhu VJ, Tu W, Rosenman MB, Overhage JM. Nonadherence to oral antihyperglycemic agents: subsequent hospitalization and mortality among patients with type 2 diabetes in clinical practice. Stud Health Technol Inform 2015;216:60-63
40. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109
41. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3. 4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990
42. Campbell SM, Reeves D, Kontopantelis E, Sibbald B, Roland M. Effects of pay for performance on the quality of primary care in England. N Engl J Med 2009;361:368-378
43. Seshasai SRK, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841
44. Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015;373:1720-1732
45. IbrahimIA, Kang E, Dansky KH. Polypharmacy and possible drug-drug interactions among diabetic patients receiving home health care services. Home Health Care Serv Q 2005;24:87-99
46. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003; 26:1408-1412
47. Austin RP. Polypharmacy as a risk factor in the treatment of type 2 diabetes. Diabetes Spectrum 2006;19:13-16
48. Emslie-Smith A, Dowall J, Morros A. The problem of polypharmacy in type 2 diabetes. BritishJournal of Diabetes & Vascular Disease 2003;3: 54-56
49. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239-245
50. HaynesRB, AcklooE, SahotaN, McDonaldHP, Yao X. Interventions for enhancingmedication adherence. Cochrane Databse Syst Rev 2008;2:CD000011
51. Heidenreich PA. Patient adherence: The next frontier in quality improvement. Am J Med 2004; 117:130-132
52. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012;29:855-862
53. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
54. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4-14
55. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355-1360